Hepatic Dysfunction Related to Thyrotropin Receptor Antibody in Patients with Graves’ Disease

 

 Buy Article Permissions and Reprints

Abstract

Background: Hepatic dysfunction is a common phenomenon in patients with Graves’ disease (GD). However, its pathogenesis is not fully understood. We aimed to determine the correlation between the thyrotropin receptor antibody (TRAb) and liver biochemical abnormalities in patients with GD.

Methods: A total of 236 consecutive unrelated inpatients with newly diagnosed and untreated GD were included. Clinical characteristics (age, gender, disease duration) were collected. The liver biochemical values were tested and serum thyroid hormones, anti-thyroid antibodies and thyroid volumes were also evaluated. The patients were divided into hepatic dysfunction (HDF) and normal hepatic function (NHF) groups according to liver biochemical values.

Results: We found that 77.9% untreated patients with GD had at least one liver function test abnormality. The levels of TRAb in patients of HDF group were significantly increased compared with those in patients of NHF group, P<0.001. Linear regression suggested that TRAb has significant correlation with AST, ALP, γ-GTP, TB and DB. Logistic regression concluded that GD patients with high levels of TRAb had a greater possibility of developing liver biochemical abnormalities (OR=1.069, 95% CI 1.019–1.113).

Conclusions: Hepatic dysfunction is common in patients with GD, and elevation of TRAb may contribute to hepatic dysfunction in patients with GD.

• References

• 1 Williams GR. Extrathyroidal expression of TSH receptor. Ann Endocrinol (Paris) 2011; 72: 68-73
  CrossrefPubMedGoogle Scholar
• 2 Zhang W, Tian LM, Han Y et al. Presence of thyrotropin receptor in hepatocytes: not a case of illegitimate transcription. J Cell Mol Med 2009; 13: 4636-4642
  CrossrefPubMedGoogle Scholar
• 3 Tian L, Song Y, Xing M et al. A novel role for thyroid-stimulating hormone: up-regulation of hepatic 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase expression through the cyclic adenosine monophosphate/protein kinase A/cyclic adenosine monophosphate-responsive element binding protein pathway. Hepatology 2010; 52: 1401-1409
  CrossrefPubMedGoogle Scholar
• 4 Thompson Jr P, Strum D, Boehm T et al. Abnormalities of liver function tests in thyrotoxicosis. Mil Med 1978; 143: 548-551
  PubMedGoogle Scholar
• 5 Kubota S, Amino N, Matsumoto Y et al. Serial changes in liver function tests in patients with thyrotoxicosis induced by Graves' disease and painless thyroiditis. Thyroid 2008; 18: 283-287
  CrossrefPubMedGoogle Scholar
• 6 Elias RM, Dean DS, Barsness GW. Hepatic dysfunction in hospitalized patients with acute thyrotoxicosis: a decade of experience. ISRN Endocrinol 2012; 2012 325092
  PubMedGoogle Scholar
• 7 Bayraktar M, Van Thiel DH. Abnormalities in measures of liver function and injury in thyroid disorders. Hepatogastroenterology 1997; 44: 1614-1618
  PubMedGoogle Scholar
• 8 Sellin JH, Vassilopoulou-Sellin R. The gastrointestinal tract and liver in thyrotoxicosis. In: Braverman LE, Utiger RD. (eds.) The Thyroid. 9^th edition Lippincott Williams&Wilkins; New York: 2005: 622-626
  Google Scholar
• 9 Khan TM, Malik S, Diju IU. Correlation between plasma thyroid hormones and liver enzymes level in thyrotoxic cases and controls in Hazara Division. J Ayub Med Coll Abbottabad 2010; 22: 176-179
  PubMedGoogle Scholar
• 10 Ittermann T, Haring R, Wallaschofski H et al. Inverse association between serum free thyroxine levels and hepatic steatosis: results from the Study of Health in Pomerania. Thyroid 2012; 22: 568-574
  CrossrefPubMedGoogle Scholar
• 11 Moustafa AH, Ali EM, Mohamed TM et al. Oxidative stress and thyroid hormones in patients with liver diseases. Eur J Intern Med 2009; 20: 703-708
  CrossrefPubMedGoogle Scholar
• 12 Bahn RS. Graves’ ophthalmopathy. N Engl J Med 2010; 362: 726-738
  Google Scholar
• 13 Singer PA, Cooper DS, Levy EG et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA 1995; 273: 808-812
  CrossrefPubMedGoogle Scholar
• 14 Bahn Chair RS, Burch HB, Cooper DS et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011; 21: 593-646
  CrossrefPubMedGoogle Scholar
• 15 Christ-Crain M, Meier C, Guglielmetti M et al. Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis 2003; 166: 379-386
  CrossrefPubMedGoogle Scholar
• 16 Tuzcu A, Bahceci M, Gokalp D et al. Subclinical hypothyroidism may be associated with elevated high-sensitive c-reactive protein (low grade inflammation) and fasting hyperinsulinemia. Endocr J 2005; 52: 89-94
  CrossrefPubMedGoogle Scholar
• 17 Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-1812
  CrossrefPubMedGoogle Scholar
• 18 Brenner C, Galluzzi L, Kepp O et al. Decoding cell death signals in liver inflammation. J Hepatol 2013; 59: 583-594
  CrossrefPubMedGoogle Scholar